URL: http://www.leukemia-net.org/content/e54/e1273/e1284/index_eng.html
-
Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A, Hasford J, Heimpel H, Hossfeld DK, Kolb H-J, Löffler H, Pralle H, Queisser W, Hehlmann R and the German CML-Study Group:
Gender aspects in chronic myeloid leukaemia: long-term results from randomized studies
Leukemia
2005; 19: 984-989
Subjects: CML
-
Hasford J:
Common Treatment Arm and Uniform Protocol Standards. A New Multicenter Trial Design
Clin Trials
2005; 2: S67
Subjects: Epidemiology
-
Hasford J, Pfirrmann M, Hochhaus A:
How long will chronic myeloid leukaemia patients treated with imatinib mesylate live?
Leukemia
2005; 19: 497-499
Subjects: Epidemiology
-
Hasford J, Pfirrmann M, Shepherd P, Guilhot J, Hehlmann R, Mahon FX, Kluin-Nelemans HC, Ohnishi K, Steegmann JL, Thaler J:
The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukaemia treated with interferon-alpha
Haematologica
2005; 90: 335-340
Subjects: Epidemiology
-
Pfirrmann M, Hasford J.:
A simulation study using validated prognostic factors to assess expected long-term survival
Methods of Information in Medicine
2005; 44: 577-583
Subjects: Epidemiology
-
Pfirrmann M, Hasford J:
A prognostic score including the time-dependent variable cytogenetic remission for risk-stratified comparison of survival between imatinib-treated patients and historical control data on IFN-treatment
Haematologica / the hematology journal
2005; 90, Suppl. 2: 43
Subjects: Epidemiology
Printing Date: 08.01.2009
© 2004-2008 ELIC European Leukemia Information Center